Establishing the immunogenicity of the first naturally presented Leishmania epitope vaccine candidates in Ethiopian cutaneous leishmaniasis
VALIDATE Fellowship - September 2024 to September 2026
Led by:
Dr Thao-Thy Pham; VALIDATE Associate; Institute of Tropical Medicine Antwerp, Belgium
Project Aims
Leishmaniasis is a severe disease with no vaccine currently available. The disease is caused by the Leishmania parasite and can lead to different clinical presentations such as the visceral lethal complications or various forms of cutaneous lesions. Previous research suggests that variations in the parasite's genes and how the host's immune system responds to these variations may influence the disease development. We suspect this could be due to differences in how the parasite's antigens are presented to the T cells of the immune system.
Recently, we used a new method called immunopeptidomics to analyse samples from lesions of patients with cutaneous leishmaniasis. This resulted in a very first list of Leishmania antigens that are actually presented to the T cells of the immune system. These results are biologically more relevant from earlier Leishmania vaccine candidates found by other groups who used bioinformatical prediction algorithms. Our immunopeptidomics findings suggest that the different clinical presentations of cutaneous leishmaniasis may show different numbers and/or types of these Leishmania antigens which further strengthens our hypothesis.
In this project, I aim to confirm whether these newly identified Leishmania antigens could indeed be promising vaccine candidates. First, I will assess if the Leishmania antigens are recognised by the host's T cells in samples of patients with cutaneous leishmaniasis, and how strong and common this recognition is. Additionally, I will develop a novel method to see if these Leishmania antigens can induce a protective T cell response which will be a crucial feature for a vaccine target. Ultimately, my goal is to speed up vaccine development for leishmaniasis, which is currently at a standstill.
Project Outcomes
Leishmaniasis remains one of the most severe neglected tropical diseases, and is endemic in 98 countries, including southern Europe and the United States. The disease is caused by an infection with the Leishmania parasite, and results in an estimated one million new cases each year. Transmission occurs via a sand fly bite, whose habitats are expected to have northward expansion due to climate change. With billions of individuals living at risk for Leishmania infection, no licensed human vaccine exists.
Previous Leishmania vaccine candidates were safe and immunogenic but failed to advance to Phase III trials, hindered by lack of therapeutic efficacy, unvalidated immune correlates of protection, high development costs, and weak commercial interest. Critically, most antigens were selected via computational prediction or animal models, not from naturally exposed humans. To address this gap, we have recently identified Leishmania antigens that are genuinely MHC-presented in clinical samples, rather than predicted by in silico algorithms (de Vrij N et al. 2026 Fron Immunol); Using the immunopeptidomics method (direct isolation of MHC-presented Leishmania peptides from infected human cells) on Ethiopian cutaneous leishmaniasis lesions, we identified 333 novel MHC-I and 247 MHC-II epitopes from 398 L. aethiopica proteins.
Of these, six candidate proteins were prioritized based on several parameters including epitoperichness, immunoprevalence across patients, and sequence conservation across Leishmania species: Elongation Factor 2, Ankyrin Repeat Protein, Ubiquitin-activating Enzyme E1, Tetratricopeptide Repeat Protein, Heat Shock Protein 70, and Vacuolar ATP Synthase Subunit B. To further validate whether these MHC-presented Leishmania antigens are actually recognized by T cells who express the parasite-killing IFN-y after T cell activation, a new two-centre clinical study was established in Ethiopia: “Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With Leishmaniasis” (LEISHVAC) registered with ClinicalTrials.gov Identifier NCT07783243. The explorative study recruits across the clinical spectrum of Leishmania exposure: healthy volunteers, patients with visceral or with cutaneous leishmaniasis (sampled both at diagnosis and at end of treatment). Immunogenicity is conventionally defined by IFN-y expression after ex vivo stimulation of host cells with overlapping peptide pools of the six Leishmania antigens.
Recruitment is approximately halfway complete and formal statistical analysis has not yet been performed. Preliminary immunogenicity data so far are encouraging; Every peptide pool elicited antigen-specific responses in exposed participants, with response magnitudes ranging up to several hundred spot-forming units. In healthy volunteers, responses were minimal or absent. Final data analysis and manuscript preparation are aimed for 2027. These data will provide the crucial immunogenicity data on these six clinically relevant Leishmania vaccine candidate antigens, and their inclusion into future Leishmania vaccine constructs.
Project Outputs
- Adriaensen W, de Vrij N, Pham TT, Laukens K, Meysman P, Kaye PM. Breaking the deadlock in antigen discovery for Leishmania vaccines. Trends Parasitol. 2026 Mar;42(3):183-191. doi: 10.1016/j.pt.2026.01.005. Epub 2026 Mar 2. PMID: 41771716.
- de Vrij N, Pepermans E, Laurijssen L, Pham T-T, Thijs L, Boonen K, Ramadan K, Maes I, Aleka Y, Kassa M, Mekonnen T, Asres MS, Woldetensay M, Hassen S, Bialfew F, Tilahun Zewdu F, Abdela SG, Domagalska MA, Cuypers B, van Henten S, van Griensven J, Meysman P, Baggerman G, Laukens K and Adriaensen W (2026) Immunopeptidomics of cutaneous leishmaniasis patients reveals the natural antigenic landscape. Front. Immunol. 17:1765843. doi: 10.3389/fimmu.2026.1765843
- Wang H, Novais FO, Gómez MA, Muhi S, de Oliveira CI, Pham TT, Vermaak S; VALIDATE Network Skin NTDs Working Group; Reljic R. Accelerating vaccine research and development for skin neglected tropical diseases: A case for leishmaniasis, leprosy, and Buruli ulcer. PLoS Negl Trop Dis. 2026 Jun 5;20(6):e0014375. doi: 10.1371/journal.pntd.0014375. PMID: 42247386; PMCID: PMC13240883.